The Lancet. Infectious diseases · 2026
Guiding principles for pragmatic randomised trials of tuberculosis treatments.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phillips Patrick P J, Schumacher Samuel G, Cassino Cara, Charalambous Salome, Chaisson Richard E, Churchyard Gavin J, Conradie Francesca, Cousins Christopher, Davies Geraint, Dorman Susan E, Esmail Hanif, Fielding Katherine, Mitnick Carole D, McNeeley David, Nahid Payam, Sanders Karen, Schildkraut Jodie A, Sloan Derek J, Velásquez Gustavo E, Hoelscher Michael, Vernon Andrew A, Lienhardt Christian
Аннотация
Tuberculosis remains a major global health challenge, despite recent advances in drug and regimen development. Pragmatic randomised trials are needed to evaluate the effectiveness, safety, and tolerability of new tuberculosis treatments under routine care conditions to appropriately inform practice guidelines and facilitate uptake. In this Review, we propose guiding principles for pragmatic tuberculosis treatment trials. Using the PRECIS-2 framework, we address eligibility, recruitment, setting, organisation of care, adherence support, outcomes, follow-up, primary analysis, data collection, and monitoring. Pragmatic trials should maximise generalisability through broad inclusion criteria, integration within routine health systems, and flexible delivery approaches while maintaining appropriate standards for participant safety and data reliability. We discuss considerations for individually randomised and cluster-randomised designs, outcome definitions, risk-proportionate monitoring, and streamlined data collection. Adoption of these principles will improve the generation of real-world evidence and facilitate global implementation of effective tuberculosis treatments.